Rezolute, Inc. (formerly AntriaBio, Inc.) — 10-Q Summary
Period and identity: The supplied filing is AntriaBio, Inc.’s Form 10-Q for the quarter ended September 30, 2016, filed November 14, 2016. It does not identify Rezolute, Inc. as the registrant; verify that this is the intended filing. The company was a preclinical-stage biotechnology business developing AB101, a potential once-weekly injectable basal insulin.
Financial performance and position
- Revenue: None; the company had generated no revenue since inception. Gross margin is not applicable.
- Operating expenses: $3.824 million, up from $3.300 million in the prior-year quarter. Research and development was $2.486 million versus $1.968 million; general and administrative expense was $1.338 million versus $1.331 million.
- Net loss: $3.816 million, compared with $3.288 million. Basic and diluted loss per share was $0.11 versus $0.14; weighted-average shares rose to 35.4 million from 24.3 million.
- Cash flow: Operating cash use was $2.968 million versus $2.514 million. Investing cash use was $0.061 million; financing provided $2.333 million. Cash declined $0.696 million to $3.366 million.
- Liquidity and assets: Current assets were $3.730 million and current liabilities $1.487 million, yielding reported working capital of approximately $2.243 million. Total assets were $10.057 million.
- Debt and liabilities: Total liabilities were $1.854 million. Convertible notes totaled $60,000, were matured and due, and accrued interest at 8%; $50,000 plus accrued interest converted to 58,350 shares on October 7, 2016. Lease commitments totaled $1.388 million.
- Equity and dilution: Common shares outstanding were 37.559 million at quarter-end. The quarter’s private placements issued 2.448 million shares and raised approximately $2.4 million net; 30.654 million warrants were outstanding at quarter-end.
Changes and notable items
- Year-over-year net loss increased about 16%; R&D expense rose about 26%, primarily reflecting hiring to support clinical-material manufacturing. G&A remained broadly flat.
- Cash was lower than at June 30, 2016, despite equity financing proceeds. Depreciation rose to $268,355 from $70,313.
- After quarter-end, additional private-placement closes issued 3.336 million units for reported gross proceeds of $3.7 million. The filing separately describes an October close of 959,091 units for $1.1 million gross; verify how these disclosures relate and the total financing proceeds.
- In November 2016, the company reported granting 28.210 million options under a newly adopted plan, a potentially significant source of future dilution.
Outlook, risks and controls
- Management said existing cash and expected operating cash flows would not sustain operations for more than one year and estimated that an additional $10 million was needed to fund operations, AB101 clinical trials and R&D through calendar year-end 2017. The company planned a larger institutional financing and said no financing was assured.
- AB101’s six-month drug-substance stability study was completed in June 2016, and clinical-scale sample batches were manufactured in the September quarter. The company was working to qualify sterile manufacturing, a key prerequisite given FDA feedback. It planned to complete financing and facility qualification before the end of the first quarter of calendar 2017, then file an IND and begin a clinical study in the first half of 2017. These were plans, not assured outcomes.
- The filing states that substantial doubt existed about the company’s ability to continue as a going concern. It cited operating losses, cash use, lack of revenue and dependence on future financing.
- Management reported ineffective disclosure controls and a material weakness involving inadequate segregation of duties, a need for a stronger control environment and limited review of complex accounting matters. No material change in internal control over financial reporting was reported during the quarter.
- The company planned a South Korean subsidiary and noted risks involving foreign regulation, political and economic conditions, financing and operations. It reported no material pending or threatened litigation and no off-balance-sheet arrangements.
Important facts for investors to verify
- Whether this AntriaBio filing is the intended Rezolute filing and whether the requested “2016 Q1” refers to the quarter ended September 30, 2016.
- Actual cash runway and financing raised after September 30, including reconciliation of the post-quarter private-placement disclosures and the stated $10 million funding need.
- Progress toward manufacturing qualification, IND submission and the planned AB101 clinical-study start, including any subsequent FDA feedback or delays.
- The terms, vesting and potential dilution from the 28.210 million options granted in November, together with outstanding warrants and shares issued after quarter-end.
- Remediation of the material weakness and the status of the matured convertible notes remaining outstanding after the October conversion.